Evidence map›Paper›PMID 29131691›Full record

ArticleCancer biology & therapy2018

A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach.

Laura Caggiari, Gianmaria Miolo, Vincenzo Canzonieri, Mariangela De Zorzi, Lara Alessandrini, Giuseppe Corona, Renato Cannizzaro, Davide Adriano Santeufemia, Antonio Cossu, Angela Buonadonna and 1 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Cancer biology & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Genes · 2020
    Article
  7. Characterizing MetastaticInternational journal of molecular sciences · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Laura Caggiaria Immunopathology and Cancer Biomarkers , IRCCS CRO National Cancer Institute , Aviano , Italy.
Gianmaria Miolob Department of Medical Oncology , IRCCS CRO National Cancer Institute , Aviano , Italy.
Vincenzo Canzonieric Pathology, IRCCS CRO National Cancer Institute , Aviano , Italy.
Mariangela De Zorzid Immunopathology and Cancer Biomarkers , IRCCS CRO National Cancer Institute , Aviano , Italy.
Lara Alessandrinie Pathology, IRCCS CRO National Cancer Institute , Aviano , Italy.
Giuseppe Coronaf Immunopathology and Cancer Biomarkers , IRCCS CRO National Cancer Institute , Aviano , Italy.
Renato Cannizzarog Gastroenterology, IRCCS CRO National Cancer Institute , Aviano , Italy.
Davide Adriano Santeufemiah Department of Medical Oncology , Sassari Hospital , Sassari Italy.
Antonio Cossui Operative Unit of Pathology , Azienda Ospedaliero Universitaria Sassari , Sassari , Italy.
Angela Buonadonnaj Department of Medical Oncology , IRCCS CRO National Cancer Institute , Aviano , Italy.
Valli De Rek Immunopathology and Cancer Biomarkers , IRCCS CRO National Cancer Institute , Aviano , Italy.
Centro di Riferimento Oncologico · ITAzienda Ospedaliero Universitaria di Sassari · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Germline mutations in CDH1, the gene coding for the E-cadherin adhesion protein, are known to cause hereditary diffuse gastric cancer. We identified a new truncating germline mutation (p.Asp538Thrfs*19) in exon 11 of the CDH1 gene in a 41-year-old male with a diffuse gastric cancer. Although he had no parental history of gastric cancer, the co-segregation study in the family detected the same mutation in his healthy 31-year-old brother. The mutation affects one of the extracellular repeat (CAD repeats) domains which is essential for the homophilic binding specificity that directs "E-cadherin" to bind with itself each others. In this case, immunohistochemical analysis showed no expression of E-cadherin in the tumor sample and was a useful prescreening tool to genetic testing. This finding was associated with a poor response to trastuzumab-based treatment.

Indexed as

AdultAntigens, CDAntineoplastic Combined Chemotherapy ProtocolsCadherinsCarcinoma, Signet Ring CellGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleProtein DomainsStomachStomach NeoplasmsTomography, X-Ray ComputedTrastuzumabTreatment OutcomeAntigens, CDCadherinsCDH1 protein, humanTrastuzumabCDH1diffuse gastric cancerE-Cadheringermline mutation

Identifiers

PMID29131691
PMCPMC5902241
OpenAlexW2769756437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.